

## Chordate participates in Feminvest's investor conference in Stockholm on October 8th

**Chordate Medical non-executive Director and main owner Caroline Lundgren Brandberg will participate in Feminvest's investor conference "Fearless" in Stockholm on October 8th. She will take part in a panel discussion on entrepreneurship within publicly traded companies and growth in the life science sector.**

"We participated in Fearless in Oslo earlier this year and received very positive response both on the Ozilia treatment method and the investment case itself. Feminvest represents a broad and strong network of investors with a particular focus on femtech and life science, where Chordate and Ozilia are a good fit given that migraine is a condition that primarily affects women," says Caroline Lundgren Brandberg, board member of Chordate Medical.

Feminvest is an acceleration network for female ownership through education, as well as an investment operation. It is currently the largest platform for female investors and entrepreneurs in the Nordics, with nearly 47,000 subscribers. Feminvest also manages a network of 300 female angel investors.

"Over the past year, we have increased our efforts to raise awareness of the company and Ozilia both among potential investors and in segments surrounding Life Science. Feminvest covers both of these groups, making it a particularly suitable forum for us," says Anders Weilandt, CEO of Chordate.

Caroline Lundgren Brandberg, MSc. in Engineering Physics, eMBA, has been a board member of Chordate Medical since 2021. Caroline is the Global Sales Director at climate-tech company Deedster and has previously worked internationally for Ericsson in various senior roles focusing on sales and marketing. She also holds several board and advisory board positions, including at Stockholm University.

### **Fearless Stockholm 2024 October Edition**

October 8th, 2024

Musikaliska Kvarteret, Nybrokajen 11, Stockholm

Read more: <https://feminvest.se/en/event/fearless-stockholm/>

### **For more information, please contact:**

Anders Weilandt, CEO

[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)

Cell: +46 733-874277

Press Release  
03 October 2024 14:55:00 CEST

**CHORDATE**  
M E D I C A L

---

### **About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

### **Attachments**

[Chordate participates in Feminvest's investor conference in Stockholm on October 8th](#)